GENERINI, SERGIO
 Distribuzione geografica
Continente #
NA - Nord America 3.036
EU - Europa 2.031
AS - Asia 407
AF - Africa 10
OC - Oceania 2
Totale 5.486
Nazione #
US - Stati Uniti d'America 3.031
RU - Federazione Russa 759
PL - Polonia 414
IE - Irlanda 229
SE - Svezia 215
IT - Italia 132
HK - Hong Kong 119
SG - Singapore 117
UA - Ucraina 81
CN - Cina 77
DE - Germania 64
FI - Finlandia 56
TR - Turchia 39
GB - Regno Unito 37
IN - India 24
CH - Svizzera 19
JO - Giordania 17
AT - Austria 11
VN - Vietnam 8
CI - Costa d'Avorio 7
KR - Corea 6
CA - Canada 5
AL - Albania 3
FR - Francia 3
SC - Seychelles 3
BG - Bulgaria 2
ES - Italia 2
AU - Australia 1
BE - Belgio 1
LU - Lussemburgo 1
NL - Olanda 1
NZ - Nuova Zelanda 1
RO - Romania 1
Totale 5.486
Città #
Santa Clara 629
Warsaw 414
Fairfield 344
Chandler 295
Dublin 229
Ashburn 191
Woodbridge 144
Jacksonville 130
Cambridge 129
Seattle 123
Wilmington 120
Singapore 93
Houston 86
Hong Kong 68
Princeton 61
Buffalo 58
Medford 48
Boardman 44
Ann Arbor 41
Altamura 40
Izmir 37
Lawrence 35
Beijing 27
Boston 25
Shanghai 23
Bern 18
Mumbai 18
New York 18
Florence 17
San Diego 17
Moscow 16
Kent 13
Vienna 11
Yubileyny 11
Dong Ket 8
West Jordan 8
Abidjan 7
Los Angeles 7
Munich 7
Norwalk 6
Milan 5
Salerno 5
Seoul 5
Andover 4
Greenwich 4
Hillsboro 4
Auburn Hills 3
Falls Church 3
Frankfurt Am Main 3
Giessen 3
Parma 3
Pune 3
Rome 3
San Mateo 3
Ankara 2
Barcelona 2
Bologna 2
Bremen 2
Caserta 2
Dearborn 2
Guangzhou 2
Hounslow 2
Indianapolis 2
Langen 2
Montréal 2
Phoenix 2
Segrate 2
Tappahannock 2
Toronto 2
Turin 2
Verona 2
Ahmedabad 1
Auckland 1
Brooklyn 1
Brussels 1
Bryant 1
Cedar Knolls 1
Costa Mesa 1
Drobeta-Turnu Severin 1
Fucecchio 1
Grosseto 1
Hebei 1
Helsinki 1
Islington 1
Kunming 1
Lachine 1
Lake Zurich 1
Leawood 1
Lissone 1
Liverpool 1
London 1
Lucca 1
Lurate Caccivio 1
Manchester 1
Monmouth Junction 1
Palermo 1
Philadelphia 1
Pine Bush 1
Portland 1
Redwood City 1
Totale 3.730
Nome #
Effect of N-acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis 249
[Peripheral nervous system in limited systemic sclerosis]. 242
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). 229
Activin, a grape seed derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. 127
DRESS syndrome in a patient with chronic hepatic encephalopathy. 126
Estrogens and neuropeptides in Raynaud's phenomenon. 125
Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis 124
Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers 123
Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. 122
Oxidative stress in Systemic Sclerosis. 118
Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNF-α. 117
Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. 117
Screening of distress among hospitalized patients in a department of internal medicine. 115
High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. 109
Somatostatin-induced modulation of inflammation in experimental arthritis 108
Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement 107
Exercise Doppler echocardiography identifies preclinic asymptomatic pulmonary hypertension in systemic sclerosis. 105
Longitudinal ultrasound and clinical follow-up of Baker's cysts injection with steroids in knee osteoarthritis. 103
Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. 102
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. 99
Diene-conjugates and antibodies against oxidized low-density lipoproteins in systemic sclerosis. 99
Urokinase-type plasminogen activator is the main plasminogen activator produced by synoviocytes of osteoarthritis and rheumatoid arthitis 95
Are Angiotensin Converting Enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease? 95
Discrepant expression of neprilysin on fibroblasts in diffuse systemic sclerosis. 94
Bcl-2, p53 and c-myc expression in juvenile dermatomyositis. 93
NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. 92
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. 91
Current Treatment Options in Raynaud's Phenomenon. 91
Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis 88
Evidence for the prevention of enthesitis in HLA-B27/hβ(2) m transgenic rats treated with a monoclonal antibody against TNF-α 87
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. 86
Postural and kinesiologic evaluation in patients with early ankylosing spondylitis. 83
Vasculitides secondary to systemic diseases. 81
Reduction of bcl-2 in T cells during immunosuppressive therapy in patients with severe juvenile onset systemic lupus erythematosus. 80
Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarciodosis 80
NEPRILYSIN LEVELS IN PLASMA AND SYNOVIAL FLUID OF JUVENILE IDIOPATHIC ARTHRITIS PATIENTS. RHEUMATOL INT. 2005 JUN;25(5):336-40. EPUB 2004 MAR 3. 79
Increased circulating nerve growth factor is directly correlated with disease activity in juvenile chronic arthritis. 79
Clinical and laboratory features and disease outcome of kawasaki disease: the analysis of our experience and literature review. 79
Evidence of immune activation against oxidized lipoproteins in inactive phases of juvenile chronic arthritis. 78
The loss of endothelium dependent vascular tone control in systemic sclerosis. 77
Raynaud's phenomenon and vascular disease in systemic sclerosis. 77
Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. 77
Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). 75
Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. 73
TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats 72
Neuropeptides and steroid hormones in arthritis. 71
Evidence for hyaluronan production in the air pouch model in rats. 71
A Sonographic (Us) Evaluation Of Ligaments Of Sacroiliac Joint In Healthy Subjects 71
The pathogenesis of inflammatory muscle diseases: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis. 58
Therapy of spondylarthropathy in inflammatory bowel disease. 53
Peripheral nervous system involvement in systemic sclerosis: the median nerve as target structure. 51
Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver 51
Systemic sclerosis. A clinical overview. 49
Iliopsoas bursitis in rheumatoid arthritis. 49
Raynaud's phenomenon and systemic sclerosis. 47
Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. 44
The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms. 43
New approaches to Raynaud's phenomenon [corrected]. 42
Erratum: "The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn) (Clinical and Experimental Rheumatol (2005) vol. 23 (5) (671-677)) 41
Totale 5.509
Categoria #
all - tutte 14.707
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.707


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020570 0 0 0 0 85 97 87 100 80 40 64 17
2020/2021488 46 37 40 45 22 66 13 41 41 65 29 43
2021/2022354 10 37 10 11 8 15 13 15 15 13 92 115
2022/20231.019 105 153 39 102 86 188 124 53 96 15 32 26
2023/2024387 14 39 63 18 34 67 15 85 2 16 25 9
2024/20251.727 80 263 189 427 768 0 0 0 0 0 0 0
Totale 5.509